Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Zealand Pharma A/S seeks a Head of Clinical Trial Documentation to lead a seven‑strong team and own TMF, trial administration, and related processes. You will oversee eTMF in Veeva Vault, ensure quality oversight of CROs and internal stakeholders, and drive readiness for inspections across global trials.
The role combines leadership with hands‑on execution, shaping how documentation quality integrates into daily collaboration with CROs, partners and project teams.
Does it excite you to lead a team and own the processes and systems behind our clinical trial documentation, and do you have experience with ICH-GCP and Trial Master File (TMF)? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position As Head of Clinical Trial Documentation, you will lead a team of seven, including Clinical Trial Administrators and a System Owner. You will own both the processes and the systems that keep our trial documentation compliant and inspection-ready. You will report to Senior Director, Head of Clinical Project Management, Rikke Ottesen, and combine leadership with hands‑on involvement. You join at a time when Clinical Operations is on a development journey, and you will help shape how we work as Zealand grows. As our CROs work directly in our eTMF, you will have a unique opportunity to build documentation quality into daily collaboration.
The Clinical Trial Documentation department is part of Clinical Operations, working closely with project teams, Quality Assurance, CROs and partners. You will join a collaborative environment built on trust, ownership and shared responsibility, with a genuine opportunity to make a visible contribution as Zealand grows.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
For further information, please contact Senior Director Clinical Project Management, Rikke Ottesen, rottesen@zealandpharma.com.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to be address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes.
In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to delivering new treatments to patients living with congenital hyperinsulinism and short‑bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease.
Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.